Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL9727812 | 0.98 | APLNR (0.38) | APLNRGAAALOX15CYP1A2GRM2 | |
| SCHEMBL13225971 | 0.80 | GAA (0.32) | GAAALOX15CYP1A2GRM2GRM3 | |
| SCHEMBL13225975 | 0.80 | GAA (0.32) | GAAALOX15CYP1A2GRM2GRM3 | |
| SCHEMBL1363759 | 0.80 | GAA (0.32) | GAAALOX15CYP1A2GRM2GRM3 | |
| SCHEMBL8183184 | 0.78 | SLC1A2 (0.43) | APLNRALOX15CYP1A2GRM2GRM3 | |
| SCHEMBL21103429 | 0.77 | CHRNB2 (0.33) | GAAPOLBEZH2ALDH1A1 | |
| SCHEMBL3166773 | 0.77 | ATM (0.36) | GAACYP1A2POLBCYP2C19MEN1 | |
| SCHEMBL12729672 | 0.75 | — | — | |
| SCHEMBL29415981 | 0.74 | APLNR (0.41) | APLNRALOX15CYP1A2GRM2GRM3 | |
| SCHEMBL24783654 | 0.74 | HSD17B10 (0.38) | GAACYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108969-A | Efficient and migration-resistant antioxidant as well as preparation method and application thereof | 华南理工大学 | 2022-09-27 | — | — | CN | claimed |
| CN-114609172-A | Method for judging drying and storage effects of rice based on molecular motion | 中南林业科技大学 | 2022-06-10 | — | — | CN | claimed |
| US-20250282702-A1 | CHEMICAL PROCESS | SYNGENTA CROP PROTECTION AG (CH) | 2025-09-11 | — | — | US | disclosed |
| EP-4519236-A1 | CHEMICAL PROCESS | Syngenta Crop Protection AG (CH) | 2025-03-12 | — | — | EP | disclosed |
| US-11827786-B2 | Resin composition and article made therefrom | ELITE ELECTRONIC MATERIAL (KUNSHAN) CO., LTD. (CN) | 2023-11-28 | — | — | US | disclosed |
| WO-2023213926-A1 | CHEMICAL PROCESS | SYNGENTA CROP PROTECTION AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| US-20230339907-A1 | PROCESS FOR THE PREPARATION OF QUATERNIZED PYRIDAZINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-10-26 | — | — | US | disclosed |
| US-20230323057-A1 | RADICAL CURABLE RESIN COMPOSITION, FIBER-REINFORCED MOLDING MATERIAL, AND MOLDED ARTICLE USING SAME | DIC CORPORATION (JP) | 2023-10-12 | — | — | US | disclosed |
| EP-4196469-A1 | PROCESS FOR THE PREPARATION OF QUATERNIZED PYRIDAZINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| EP-4174127-A1 | RADICAL CURABLE RESIN COMPOSITION, FIBER-REINFORCED MOLDING MATERIAL, AND MOLDED ARTICLE USING SAME | DIC Corporation (JP) | 2023-05-03 | — | — | EP | disclosed |
| CN-113845460-B | Curcumin derivative with photosensitive bactericidal activity, preparation method and fresh shrimp photodynamic sterilization and preservation method | 浙江海洋大学 | 2023-02-14 | — | — | CN | disclosed |
| US-6410792-B1 | OBESITY DISEASES | BAYER CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-6218452-B1 | INCORPORATING THEREIN A COMPOUND HAVING AT LEAST ONE STERICALLY HINDERED AMINO GROUP | CLARIANT FINANCE (BVI) LIMITED (VG) | 2001-04-17 | — | — | US | disclosed |
| US-6048900-A | FOR TREATING EATING DISORDERS, INSULIN RESISTANT DIABETES, HYPERTENSION, HYPERLIPEMIA | BAYER CORPORATION (US) | 2000-04-11 | — | — | US | disclosed |
| US-5932640-A | STERICALLY HINDERED N,N*-BIS/TETRAMETHYL-4-PIPERIDINO/ISOPHTHALAMIDES | CLARIANT FINANCE (BVI) LIMITED (VG) | 1999-08-03 | — | — | US | disclosed |
| EP-0618256-A2 | Improved dyeability of synthetic polyamide | SANDOZ AG (CH) | 1994-10-05 | — | — | EP | disclosed |
| US-5087752-A | Oxidizing secondary amine | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 1992-02-11 | — | — | US | disclosed |
| EP-0379470-A2 | Improved dyeability of synthetic polyamide | SANDOZ AG (CH) | 1990-07-25 | — | — | EP | disclosed |
| US-4925652-A | NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-05-15 | — | — | US | disclosed |
| US-4845090-A | NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339907-A1 | PROCESS FOR THE PREPARATION OF QUATERNIZED PYRIDAZINE DERIVATIVES | DHPS, PDXK, NQO1 | APLNR 4476/4885GAA 2066/4885ALOX15 1168/4885 |
| US-20250282702-A1 | CHEMICAL PROCESS | CYP1A1, CYP3A4, CYP1B1 | APLNR 4718/4885GAA 220/4885ALOX15 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.